Scholar Rock Holding (SRRK)
NASDAQ:SRRK
Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$49.96
-$0.51(-1.26%)
At close: 4:00 PM EST
$49.96
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$27.07 - $52.19
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.24M
Market Cap
$5.46B
Enterprise Value$5.68B
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 12, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume1,266,506
30 Day Avg. Volume1,240,383
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.56K
Enterprise Value/Ebitda-14.25
Forecast
1Y Price Target
$60.36Price Target Upside20.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
BLA Acceptance With PDUFA DateBLA acceptance with a defined PDUFA date materially reduces binary regulatory timing risk and creates a clear near‑term path to commercialization. Over the next 2–6 months this supports de‑risking the lead program, enables conditional financing plans tied to approval, and shifts the company toward potential product revenue and milestone monetization if approved.
Dual Fill‑finish Manufacturing PathHaving an independent second fill‑finish facility reduces single‑site supply risk and strengthens launch readiness. This structural redundancy improves the probability of uninterrupted commercial supply upon approval, mitigates manufacturing bottleneck risk, and supports sustainable market access and revenue generation during initial commercialization.
Substantial Cash And Financing OptionalityA large cash balance plus proven access to ATM proceeds, an approval‑linked debt facility, and a planned PRV monetization provide tangible runway and financing flexibility. Structurally, this reduces near‑term dilution pressure, funds pre‑launch investment and commercial buildout, and supports operations through a regulatory decision window.
Bears Say
No Product Revenue; Widening Net LossesPersistent zero product revenue alongside rapidly widening losses and negative operating performance means Scholar Rock remains structurally dependent on external capital. This ongoing cash burn undermines self‑sufficiency, raises dilution and refinancing risk, and pressures long‑term viability if regulatory or commercial timelines slip.
Rising Debt And Higher LeverageA marked increase in debt and leverage reduces financial flexibility and raises fixed obligations while operating cash flows remain negative. Higher leverage amplifies refinancing and interest‑rate exposure, limiting the company's ability to absorb delays or execute opportunistic investments during commercialization without additional costly financing.
Catalent Indiana Classification UncertaintyPending FDA classification of the Catalent Indiana site represents a material regulatory contingency that could affect approvability and the EU timeline. An adverse classification could delay approval, force alternative supply scaling, or complicate labeling and payer discussions, extending pre‑commercial burn and increasing execution risk.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $52.19 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $5.46B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.36 (20.82% Upside)
$60.36 (20.82% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.78%
12-Months-Change
Fundamentals
Return on Equity
-163.52%
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$60.36
▲(20.82% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.61% Insiders
28.70% Mutual Funds
15.99% Other Institutional Investors
24.78% Public Companies and
Individual Investors